Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease hyperthermia
Symptom C0027947|neutropenia
Sentences 48
PubMedID- 23989947 Dose-limiting toxicities (dlts) were evaluated during cycle 1 and were defined as follows: anc <0.5 × 109 per l for >5 days; grade 3 neutropenia with fever (⩾38.5 °c), sepsis or other severe infection; platelet count <25.0 × 109 per l; any other grade 3/4 nonhaematological adverse event (ae) suspected to be treatment related (except for nausea/vomiting without an optimal antiemetic regimen, hypersensitivity reactions and nonclinically relevant biochemical abnormalities); and any delays in the administration of a subsequent plitidepsin dose exceeding 2 weeks, or omissions of the infusions scheduled on days 8 and 15 because of treatment-related aes.
PubMedID- 20351213 The purpose of this study was to evaluate the clinical utility of bacterial rrna-targeted reverse transcription-quantitative pcr (brrna rt-qpcr) assays for identifying the bacterial pathogens that cause fever with neutropenia in pediatric cancer patients, by comparing the bacterial detection rate of this technique with that of blood culture.
PubMedID- 24455636 Background: neutropenia with fever is a common syndrome in patients with hematologic malignancies who have a high risk of infectious diseases.
PubMedID- 20878160 Of the six patients treated at dose level 1, 2 had grade 3 neutropenia with fever lasting 5 days, 1 had grade 2 anemia, and 1 had grade 2 thrombocytopenia.
PubMedID- 24793316 Dengue fever as a cause of febrile neutropenia in adult acute lymphoblastic leukemia: a single center experience.
PubMedID- 21285987 Dlts were defined as grade 4 neutropenia associated with fever (⩾38.5°c) or diarrhoea ⩾ grade 2, grade 4 neutropenia lasting ⩾5 days without fever, grade 4 thrombocytopenia for ⩾5 days, grade 3 or higher non-haematological toxicity (except liver transaminase elevation, or nausea or vomiting treatable by anti-emetic), and treatment delay >2 weeks before start of next cycle of treatment because of unresolved toxicity.
PubMedID- 25409861 neutropenia with or without fever is a relevant cause of morbidity, mortality and costs, compromising treatment administration and clinical outcomes.
PubMedID- 23836852 Severe transient neutropenia with fever and abdominal pain in a 30-year-old man.
PubMedID- 26524019 Methods: blood samples obtained from 76 fever patients with al during neutropenia episodes were detected to analyse single nucleotide polymorphism (snp) in the mbl exoni 54 and nfkappab1-94ins/del attg gene, and analyse the correlation between above-menthioned 2 polymorphisms and fever during neutropenia of al patients after chemotherapy.
PubMedID- 25345994 fever and fever with neutropenia (fn) were the two most common diagnoses, accounting for almost 20% of visits.
PubMedID- 21563549 Except for neutropenia with neutropenic fever and alopecia, no nci-ctc grade iii or iv toxicity was observed.
PubMedID- 22240796 A dlt was defined as any tak-285-related grade 4 haematological toxicity, grade 3 or worse non-haematological toxicity, grade 3 or worse neutropenia (<1000 mm–3) with fever of 38 °c or higher, or toxicity resulting in cessation of treatment for >21 consecutive days (including the stipulated period of observation without treatment).
PubMedID- 23975510 One of 6 patients at dose level 2 (5 mg everolimus) had grade 3 hepatotoxicity and 3 of 6 patients at level 3 (7.5 mg everolimus) had grade 4 hematologic toxicities (two grade 4 thrombocytopenia and one grade 4 neutropenia with fever lasting more than 3 days).
PubMedID- 25671574 Virtually applying different tldfs, the number of episodes of fever (with or without neutropenia) increased from 124 at limitstandard to 291 (235%) at 38.5°c, to 604 (487%) at 38.0°c, and to 1191 (960%) at 37.5°c.
PubMedID- 21559248 Dose-limiting toxicity was defined as grade 3 fatigue persisting for ≥7 days or grade 4 fatigue; grade 3 or 4 nausea, diarrhea, or vomiting despite maximum supportive care; symptomatic pulmonary embolism (incidental asymptomatic pulmonary embolism or deep vein thrombosis identified during routine tumor imaging procedures was not dlts); grade 3 or 4 neutropenia with fever >38.5°c; grade 4 neutropenia (absolute neutrophil count <0.5 × 109/l) or thrombocytopenia (platelet count <25 × 109/l) for >7 days; grade 4 hypertension; grade 4 rash/desquamation; grade 4 hypertension; ast or alt >10 × uln; symptomatic hypomagnesemia despite intravenous magnesium replacement; any other motesanib- and/or panitumumab-related grade 4 hematologic or grade 3 nonhematologic toxicity that was unacceptable in duration during the dlt period (cycle 1).
PubMedID- 21540759 fever with severe neutropenia was more common in patients with lrti than with urti (p = 0.02).
PubMedID- 20564143 The dose-limiting toxicities (dlts) were fever with grade 3/4 neutropenia, grade 3 fatigue, and grade 3 mucositis.
PubMedID- 20579327 neutropenia with fever occurred in 8% of dogs after treatment with vinblastine and in 2% after treatment with ccnu.
PubMedID- 25961061 The maximal tolerated dose (mtd) for daily iv infusions was 30 μg/kg, and dose-limiting toxicities consisted of hepatotoxicity, neutropenia, and lightheadedness with fever and rigors.
PubMedID- 25931813 If an adverse event required dose interruption, the nab-paclitaxel dose was reinitiated at the start of a treatment cycle if the patient’s absolute neutrophil count was ≥ 1,500 cells/µl, the patient's platelet count was ≥ 100,000 cells/µl, and any other toxicity resolved to grade 1. patients experiencing grade 3–4 neutropenia, with or without fever, or grade 2 symptomatic anemia could receive hematological support with granulocyte colony-stimulating factor or erythropoietin.
PubMedID- 22588015 One such life-threatening complication in immunocompromised children remains infection, which frequently manifests as the occurrence of fever with neutropenia 4.
PubMedID- 25684313 Treatment had to be stopped early in eight (19%) patients, mainly due to limiting toxicity in five patients (diarrhea, febrile neutropenia, neutropenia without fever, diarrhea with febrile neutropenia, and skin toxicity), one toxic death (colonic perforation), one acute pancreatitis, and one consent withdrawal.
PubMedID- 25395866 neutropenia, duration of neutropenia, fever, duration of fever, and c-reactive protein (crp) were evaluated throughout the study.
PubMedID- 24064965 Molecular-based diagnosis of bacteremia in the setting of fever with or without neutropenia in pediatric hematology-oncology patients.
PubMedID- 21747881 Stomatitis caused by toxicity greater than grade ii was observed in 39% of the patients .
PubMedID- 22754210 Most congenital neutropenia is diagnosed because of fever and severe infection in infants and young children.
PubMedID- 25943747 Granulocyte colony-stimulating factors were allowed in grade 3 neutropenia with fever lasting ≥3 days or in case of grade 4 neutropenia.
PubMedID- 23088794 The overall favorable response rate (rr) was 64.8% when the resolution of fever during neutropenia was included in the response criteria and 84.5% when excluded.
PubMedID- 22606398 Filgrastim as a rescue therapy for persistent neutropenia in a case of dengue hemorrhagic fever with acute respiratory distress syndrome and myocarditis.
PubMedID- 21610706 Dose-limiting toxicity was defined as one of the following adverse events (aes) occurring during cycle 1: grade 4 haematological toxicity; grade 3 neutropenia with infection or fever ⩾38.5°c; grade ⩾3 non-haematological treatment-related toxicity, except toxicities which had not been maximally treated (such as nausea, vomiting and diarrhoea) or that the patient considered tolerable (such as skin rash); confirmed grade 3 qtc prolongation (qtc >500 ms) persisting after correction of other possible causes such as electrolyte imbalance or hypoxia; or inability to receive the next dose of pd 0332991 within 1 week (±1 day) of the last dose because of lack of haematological recovery or prolonged non-haematological toxicity grade ⩾3.
PubMedID- 23293699 Grade 3 fatigue, dehydration, diarrhea, neutropenia with or without fever, lymphopenia, anemia, hyperbilirubinemia, and transaminitis occurred in >/=10% of the patients.
PubMedID- 23943780 neutropenia in patients with shanghai fever was probably induced by p aeruginosa infection rather than a predisposing factor for the infection.
PubMedID- 22395759 Purpose of review: fever in neutropenia is the most frequent potentially life-threatening complication of chemotherapy in children and adolescents with cancer.
PubMedID- 20509945 Only patients that presented fever during neutropenia (defined as a neutrophil count <500 μl) were included in the second phase of the study.
PubMedID- 23963141 None of the six patients entered at dose level 1 experienced dlt in cycle 1, allowing escalation to dose level 2. at dose level 2, one out of the six patients experienced dlt (fever with grade 4 neutropenia and grade 3 thrombocytopenia, leading to death) in cycle 1, allowing escalation to dose level 3. at dose level 3, the first (grade 4 thrombocytopenia) and the third (grade 3 hyperglycemia) patients experienced dlts during cycle 1; thus, level 2 was regarded as the highest well-tolerated dose and this cohort was expanded by an additional six patients to obtain additional safety and pharmacokinetic data.
PubMedID- 23080291 Of the 71 patients who developed neutropenia, the proportion of children who developed fever was significantly lower in the ciprofloxacin group than in the placebo group (17/34 50.0% versus 27/37 73.0%; absolute difference in risk, -23.0%; 95% confidence interval: -45.0% to -0.9%; p = 0.046).
PubMedID- 22050689 Mbl2 and fever during neutropenia in children with acute lymphoblastic leukaemia.
PubMedID- 19735276 Fifty-six episodes of persistent fever with neutropenia requiring eaft were recorded among 49 patients.
PubMedID- 22333598 For haematological toxicities, dlt was defined as a grade 4 neutropenia with fever, grade 4 neutropenia without fever for ⩾7 days, or grade 4 thrombocytopenia.
PubMedID- 23228190 Dose limiting toxicity (dlt) was defined as grade 3 neutropenia with fever or infection; grade 4 neutropenia persisting ≥ 7 days; grade 3 thrombocytopenia with bleeding or grade 4 thrombocytopenia > 7 days; any non-hematological toxicity grade 3 or 4 except alopecia, nausea and vomiting; increase in urinary retention parameters ≥ grade 2; peripheral sensory neuropathy ≥ grade 3. relation between study drug and toxicity was evaluated with respect to the differences of the side effects of fluoruracil/leucovorin and capecitabine.
PubMedID- 24434034 neutropenia with fever (febrile neutropenia fn) is a serious consequence of myelosuppressive chemotherapy that usually results in hospitalization and the need for intravenous antibiotics.
PubMedID- 21883896 Serum cea levels were even increased under everolimus 5 mg a day as compared to baseline and mildly decreased after increasing the dose to 10 mg. then, because of insurgence of grade 2 anaemia and grade 3 neutropenia with fever and need of antibiotic therapy, everolimus was discontinued until recovery to grade 1 haematological toxicity.
PubMedID- 21791058 A dlt was defined as treatment-related grade 3 fatigue for ≥ 7 days or grade 4 fatigue; grade 3 or 4 nausea/vomiting despite maximum supportive care; grade 3 neutropenia with fever > 38.5°c or grade 4 neutropenia; grade 4 thrombocytopenia for ≥ 7 days; grade 4 anemia; grade 4 hypertension; alanine aminotransferase or aspartate aminotransferase > 10 times the upper limit of normal; grade 3 rash for ≥ 7 days despite maximum supportive care or grade 4 rash; grade 3 diarrhea for ≥ 7 days despite maximum supportive care or grade 4 diarrhea; or any other treatment-related hematologic or nonhematologic grade 3 or 4 toxicity (except alopecia) occurring in the first 5 weeks of treatment.
PubMedID- 21373895 Dose-limiting toxicity (dlt) during cycle 1 included: (1) neutrophil nadir < 500/mul attributed to therapy, (2) platelet nadir < 50,000/mul attributed to therapy, (3) grade 3-4 non-hematologic toxicity attributed to therapy, and (4) neutropenia associated with grade 2 fever (i.e., febrile neutropenia).
PubMedID- 26421015 Adult filipino febrile neutropenia patients with prolonged fever >7 days prior to admission, known pathogen on cultures, and nadir anc < 100 during admission were at significant risk of developing worse outcomes, whereas those with g-csf use and complete antibiotic therapy were significantly associated with better outcomes.
PubMedID- 22479278 Dlts were defined as grade 4 neutropenia associated with fever for more than 3 days; grade 4 neutropenia lasting for more than 10 days; grade 3-4 thrombocytopenia with grade 2 hemorrhage; or grade 3-4 non-hematologic toxicity during the first treatment cycle.
PubMedID- 22661287 Common terminology criteria of adverse events (ctcae) grade >/= 3 neutropenia (with or without fever) occurred in 34% of patients overall.
PubMedID- 25444524 Study design: episodes of fever without neutropenia (absolute neutrophil count anc >/=500 cells/mm(3)) were reviewed retrospectively in pediatric oncology patients with a cvc undergoing chemotherapy.

Page: 1